ArticlePloS one2011
GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Fibrinogen-like protein 2 in gastrointestinal stromal tumour.Journal of cellular and molecular medicine · 2022Article
- Cellular and molecular outcomes of glutamine supplementation in the brain of succinic semialdehyde dehydrogenase-deficient mice.JIMD reports · 2020Article
- Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.Oncology reports · 2020Article
- aTEMPO: Pathway-Specific Temporal Anomalies for Precision Therapeutics.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2020Article
- Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours.Journal of cellular and molecular medicine · 2018Article
- KAOS: a new automated computational method for the identification of overexpressed genes.BMC bioinformatics · 2016Article
- Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.BMC genomics · 2016Article
- REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.PloS one · 2016Article
- CSAX: Characterizing Systematic Anomalies in eXpression Data.Journal of computational biology : a journal of computational molecular cell biology · 2015Article
- Article
- ZODET: software for the identification, analysis and visualisation of outlier genes in microarray expression data.PloS one · 2014Article
- Pathway-based outlier method reveals heterogeneous genomic structure of autism in blood transcriptome.BMC medical genomics · 2013Article
- Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine.Genome medicine · 2013Article
- HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation.Oncogene · 2012Article
- Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.PloS one · 2012Article
- Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks.Advances in bioinformatics · 2012Article
- A cell spot microarray method for production of high density siRNA transfection microarrays.BMC genomics · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeta-analysis of gene expression microarray datasets presents significant challenges for statistical analysis. We developed and validated a new bioinformatic method for the identification of genes upregulated in subsets of samples of a given tumour type ('outlier genes'), a hallmark of potential oncogenes. METHODOLOGY: A new statistical method (the gene tissue index, GTI) was developed by modifying and adapting algorithms originally developed for statistical problems in economics. We compared the potential of the GTI to detect outlier genes in meta-datasets with four previously defined statistical methods, COPA, the OS statistic, the t-test and ORT, using simulated data. We demonstrated that the GTI performed equally well to existing methods in a single study simulation. Next, we evaluated the performance of the GTI in the analysis of combined Affymetrix gene expression data from several published studies covering 392 normal samples of tissue from the central nervous system, 74 astrocytomas, and 353 glioblastomas. According to the results, the GTI was better able than most of the previous methods to identify known oncogenic outlier genes. In addition, the GTI identified 29 novel outlier genes in glioblastomas, including TYMS and CDKN2A. The over-expression of these genes was validated in vivo by immunohistochemical staining data from clinical glioblastoma samples. Immunohistochemical data were available for 65% (19 of 29) of these genes, and 17 of these 19 genes (90%) showed a typical outlier staining pattern. Furthermore, raltitrexed, a specific inhibitor of TYMS used in the therapy of tumour types other than glioblastoma, also effectively blocked cell proliferation in glioblastoma cell lines, thus highlighting this outlier gene candidate as a potential therapeutic target. CONCLUSIONS/SIGNIFICANCE: Taken together, these results support the GTI as a novel approach to identify potential oncogene outliers and drug targets. The algorithm is implemented in an R package (Text S1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.